Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer

doi:10.3969/j.issn.1673-8640.2023.07.004

Abstract

Abstract:

Objective To investigate the relationship between the expression of PFTAIRE protein kinase 1（PFTK1） and microvessel density（MVD） and postoperative prognosis in non-small cell lung cancer（NSCLC） patients. Methods A total of 88 NSCLC patients who underwent surgical treatment at Henan Nanyang Central Hospital from January 2013 to January 2015 were enrolled. Cancer tissues and adjacent tissues（>2 cm from tumor edges） were collected，and PFTK1 expression and MVD count were determined. Spearman correlation analysis was used to evaluate the correlation between PFTK1 expression and MVD count. Kaplan-Meier survival curve and Log rank χ² test were used to analyze the survival status of NSCLC patients. Multivariate Cox regression analysis was used to evaluate the risk factors for prognosis（death） in NSCLC patients. Results Among the 88 NSCLC patients，the total positive rate of PFTK1 was 70.45%（62/88）. There was statistical significance in PFTK1 positive rate and MVD count among NSCLC patients with different TNM stages，tumor diameters and lymph node metastasis（P<0.001，P<0.05），while there was no statistical significance in PFTK1 positive rate and MVD count among NSCLC patients with different sex，ages，pathological classification and histological grading（P>0.05）. MVD count in PFTK1 positive group was higher than that in PFTK1 negative group（P<0.05）. Spearman correlation analysis showed a positive correlation between PFTK1 expression and MVD count（r=0.952，P<0.001）. Multivariate Cox regression analysis showed that TNM stage Ⅲ，lymph node metastasis，tumor diameter >3 cm and PFTK1 positivity were independent risk factors for prognosis（death） in NSCLC patients（P<0.05）. Conclusions PFTK1 is highly expressed in cancer tissues of NSCLC patients，and it is closely related to MVD count and patient prognosis.

Key words: PFTAIRE protein kinase 1, Microvessel density, Non-small cell lung cancer

CLC Number:

R446.1

CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer[J]. Laboratory Medicine, 2023, 38(7): 634-639.

Figures/Tables 5

References 21

[1]	ALMQUIST D, KHANAL N, SMITH L, et al. Preoperative pulmonary function tests(PFTs) and outcomes from resected early stage non-small cell lung cancer(NSCLC)[J]. Anticancer Res, 2018, 38(5):2903-2907.
[2]	HU H, ZHOU Y, ZHANG M, et al. Prognostic value of RASSF1A methylation status in non-small cell lung cancer(NSCLC) patients:a meta-analysis of prospective studies[J]. Biomarkers, 2019, 24(3):207-216. DOI URL
[3]	翟晓然, 江妹, 赵晓婷, 等. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3):231-235.
[4]	LI J L, YE W T, LIU Z Y, et al. Comparison of microvascular perfusion evaluation among IVIM-DWI,CT perfusion imaging and histological microvessel density in rabbit liver VX2 tumors[J]. Magn Reson Imaging, 2018, 46:64-69. DOI URL
[5]	NTELLAS P, PERIVOLIOTIS K, DADOULI K, et al. Microvessel density as a surrogate prognostic marker in patients with multiple myeloma:a meta-analysis[J]. Acta Haematol, 2017, 138(2):77-84. DOI URL
[6]	陈艺, 张腾龙, 杨哲, 等.IL-33、肿瘤微血管密度及淋巴管密度在非小细胞肺癌中的表达及对预后的影响[J]. 新医学, 2020, 51(5):370-377. DOI
[7]	李佩文. 肺癌综合诊疗学[M]. 北京: 中国中医药出版社, 2001.
[8]	WALIA R, JAIN D, MADAN K, et al. P40 & thyroid transcription factor-1 immunohistochemistry:a useful panel to characterize non-small cell lung carcinoma-not otherwise specified(NSCLC-NOS) category[J]. Indian J Med Res, 2017, 146(1):42-48. DOI URL
[9]	王雪莲, 孙丽华. 弥漫大B细胞淋巴瘤CD68和CD34表达情况及临床价值[J]. 检验医学与临床, 2023, 20(4):518-522.
[10]	SAITO Â, SOUZA E E, COSTA F C, et al. Human regulatory protein Ki-1/57 is a target of sumoylation and affects PML nuclear body formation[J]. J Proteome Res, 2017, 16(9):3147-3157. DOI PMID
[11]	MIYAGAKI H, YAMASAKI M, MIYATA H, et al. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer, 2012, 106(5):947-954. DOI
[12]	SUN T, CO N N, WONG N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2014, 449(1):163-168. DOI URL
[13]	LIU M H, SHI S M, LI K, et al. Knockdown of PFTK1 expression by RNAi inhibits the proliferation and invasion of human non-small lung adenocarcinoma cells[J]. Oncol Res, 2016, 24(3):181-187. DOI URL
[14]	ZHENG L, ZHOU Z, HE Z. Knockdown of PFTK1 inhibits tumor cell proliferation,invasion and epithelial-to-mesenchymal transition in pancreatic cancer[J]. Int J Clin Exp Pathol, 2015, 8(11):14005-14012.
[15]	李祚品, 张平安. 血清AFP、TK1、DKK1联合检测对原发性肝癌的诊断价值[J]. 现代中西医结合杂志, 2016, 25(1):94-95.
[16]	方堃, 侯红, 王启堂, 等. 胸苷激酶1在良恶性乳腺肿瘤中的表达[J]. 中华内分泌外科杂志, 2017, 11(5):377-379.
[17]	杨海杰, 崔阳阳, 王磊, 等. 细胞周期蛋白依赖性激酶PFTK1在少突胶质前体细胞分化中的潜在作用[J]. 中国组织工程研究, 2015, 19(7):1008-1012.
[18]	ZHOU Y, JIN G, MI R, et al. Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane[J]. Oncotarget, 2017, 8(22):35877-35889. DOI PMID
[19]	LI J, GU J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients:a meta-analysis of 77 randomized controlled trials[J]. Clin Drug Investig, 2018, 38(12):1109-1123. DOI
[20]	范亚峰, 崔晓燕, 虞中平, 等. Gab2基因在肺癌细胞表达及对癌细胞凋亡及Wnt/β-catenin信号通路的影响[J]. 肿瘤学杂志, 2019, 25(3):213-217.
[21]	杨小林. 非小细胞肺癌患者埃兹蛋白、血管抑制蛋白1的表达与微血管密度的相关性研究[J]. 标记免疫分析与临床, 2019, 26(2):259-263.

临床病理特征	例数	PFTK1				MVD
临床病理特征	例数	弱阳性/例	中等阳性/例	强阳性/例	总阳性率/%	MVD
性别
女性	37	8	8	10	70.27	38.52±5.25
男性	51	10	12	14	70.59	37.14±4.89
统计值					0.001	1.267
P值					0.975	0.209
年龄
≤55.6岁	46	10	12	11	71.74	36.85±4.95
>55.6岁	42	8	8	13	69.05	38.85±5.02
统计值					0.076	1.880
P值					0.782	0.063
TNM分期
Ⅰ~Ⅱ期	62	14	16	10	64.52	31.25±3.58
Ⅲ期	26	4	5	13	84.62	45.74±6.85
统计值					4.606	10.217
P值					0.032	<0.001
淋巴转移
无	53	13	12	7	60.38	30.58±3.89
有	35	5	8	17	85.71	46.56±8.42
统计值					6.501	10.512
P值					0.011	<0.001
病理类型
腺癌	62	12	13	19	70.97	37.59±5.78
鳞癌	26	6	7	5	69.23	38.56±5.54
统计值					0.027	0.727
P值					0.871	0.469
肿瘤直径
≤3 cm	42	12	9	4	59.52	32.54±4.14
>3 cm	46	6	11	20	80.43	40.28±7.20
统计值					4.612	6.247
P值					0.032	<0.001
组织学分级
中、高分化	73	15	17	21	72.60	37.58±6.41
低分化	15	3	3	3	60.00	39.42±5.52
统计值					0.441	0.972
P值					0.507	0.334

临床病理特征	例数	PFTK1				MVD
临床病理特征	例数	弱阳性/例	中等阳性/例	强阳性/例	总阳性率/%	MVD
性别
女性	37	8	8	10	70.27	38.52±5.25
男性	51	10	12	14	70.59	37.14±4.89
统计值					0.001	1.267
P值					0.975	0.209
年龄
≤55.6岁	46	10	12	11	71.74	36.85±4.95
>55.6岁	42	8	8	13	69.05	38.85±5.02
统计值					0.076	1.880
P值					0.782	0.063
TNM分期
Ⅰ~Ⅱ期	62	14	16	10	64.52	31.25±3.58
Ⅲ期	26	4	5	13	84.62	45.74±6.85
统计值					4.606	10.217
P值					0.032	<0.001
淋巴转移
无	53	13	12	7	60.38	30.58±3.89
有	35	5	8	17	85.71	46.56±8.42
统计值					6.501	10.512
P值					0.011	<0.001
病理类型
腺癌	62	12	13	19	70.97	37.59±5.78
鳞癌	26	6	7	5	69.23	38.56±5.54
统计值					0.027	0.727
P值					0.871	0.469
肿瘤直径
≤3 cm	42	12	9	4	59.52	32.54±4.14
>3 cm	46	6	11	20	80.43	40.28±7.20
统计值					4.612	6.247
P值					0.032	<0.001
组织学分级
中、高分化	73	15	17	21	72.60	37.58±6.41
低分化	15	3	3	3	60.00	39.42±5.52
统计值					0.441	0.972
P值					0.507	0.334

项目	单因素分析		多因素分析
项目	HR值（95%CI）	P值	HR值（95%CI）	P值
年龄	1.568（0.895~2.698）	0.265
性别	3.245（2.185~8.265）	0.562
TNM分期	12.986（6.895~23.654）	<0.001	7.256（2.351~21.452）	0.002
组织学分级	3.245（2.185~8.265）	0.562
淋巴转移	2.315（1.023~3.687）	0.001	2.258（1.052~3.785）	0.001
病理类型	3.025（3.547~10.285）	0.625
PFTK1表达	5.315（2.689~12.685）	<0.001	5.689（1.589~13.254）	<0.001
肿瘤直径	3.230（4.258~8.658）	0.042	4.253（3.252~12.586）	0.012

项目	单因素分析		多因素分析
项目	HR值（95%CI）	P值	HR值（95%CI）	P值
年龄	1.568（0.895~2.698）	0.265
性别	3.245（2.185~8.265）	0.562
TNM分期	12.986（6.895~23.654）	<0.001	7.256（2.351~21.452）	0.002
组织学分级	3.245（2.185~8.265）	0.562
淋巴转移	2.315（1.023~3.687）	0.001	2.258（1.052~3.785）	0.001
病理类型	3.025（3.547~10.285）	0.625
PFTK1表达	5.315（2.689~12.685）	<0.001	5.689（1.589~13.254）	<0.001
肿瘤直径	3.230（4.258~8.658）	0.042	4.253（3.252~12.586）	0.012